APIRx has twenty-two (22) active clinical and pre-clinical...

• APIRx hastwenty-two (22) active clinical and pre-clinical research and development projects
• therapeutic candidates are targeted at treating pain, dementia, Parkinson's disease, restless leg syndrome, gastrointestinal diseases, periodontitis, addiction disorders, skin conditions and ophthalmic conditions
• therapeutic candidates are underpinned by an extensive intellectual property portfolio that includes 19 granted patents and 23 pending patents
• proposed acquisition price of US$93.3M in all scrip transaction
• the transaction affirms Incannex's position as a global leader in the fields of cannabinoid, psychedelic, and combination pharmaceuticals.
• Dr Anastassov and Mr Changoer are experienced clinical researchers with medical and scientific backgrounds. They will be employed by Incannex on a full-time basis following completion of the acquisition and will continue to drive the development of APIRx projects, whilst also assisting with the development of the Company's existing projects. They are experienced with liaising and negotiating with the U.S. Food and Drug Administration ('FDA'), having undertaken numerous pre- investigational new drug ('IND') meetings, and opening two (2) IND applications for the MedChew RL and the MedChew Dronabinol medicinal product candidates. Furthermore, APIRx has strong relationships with international academic institutions and research hospitals including Mount Sinai School of Medicine, New York (USA), University of St. Andrews (UK), Free University of Amsterdam (NL), University of Wageningen (NL), and Mauritsclinics (NL).

	lincial Project	Addressable Market Opportunity ($US)	Stage of Development	Regulatory Stage of	Next Steps	Relevant
1	Development	Patents
2
3	Medchew-1401
4	Pain and Spasticity in	$62 Bn (Global) in '21 (a)	Pre-clinical	Pre-IND completed in NL	Phase 1	Granted
5	Multiple Sclerosis	and Switzerland
6
7	Medchew GB
8	Post-herpatic Neuralgia	$3.7 Bn (U.S.) by '27 (n)	Pre-clinical	FDA Pre-IND	Phase 1	Granted
9	Medchew-1502
10	Parkinson's Disease	$8.05 Bn (Global) by '27; 6.5% CAGR (l)	Pre-clinical	FDA Pre-IND	Phase 1	Granted
11	Medchew-1503
12	Dementia	$23.9 Bn (Global) by '28; 7.9% CAGR (m)	Pre-clinical	FDA Pre-IND	Phase 1	Granted
13	Medchew RL
14	Restless Leg Syndrome	12.1.% prevalence of US pop. (j)	Pre-clinical	FDA Pre-IND	Phase 1	Granted
15	Medchew Dronabinol
16	Nausea and Vomiting in	$3.1 Bn (Global) by '24 (e)	Phase 1A completed	FDA Pre-IND complete	Phase 1B	Granted
17	Chemotherapy
18
19	APIRx 1505 Flotex
20	Gastro: Chrohn's Disease	$12.6 Bn (Global) by '24 (k)	Pre-clinical	Pre-regulatory	Phase 1	Drafting
21	CanChew Plus
22	Gastro: IBS	$40 Bn (U.S.) in '21 (d)	Phase 2A Completed	Pre-IND, ethic's approval	Phase 2B	Granted
23	CanChew RX
24	Gastro: IBD	$2.7B Bn (U.S.) by '28 (r)	Pre-clinical	Pre-regulatory	Phase 1	Granted
25	SuppoCan (Suppository)
26	Gastro: IBD	$2.7B Bn (U.S.) by '28 (r)	Pre-clinical	Pre-regulatory	Phase 1	Granted
27	Oraximax
28	Gingivitis and Periodontitis	$42 Bn (U.S. and Europe) in '21 (a)	Clinical Stage	510K pre-market	Phase 2	Granted
29	submission to FDA
30
31	CheWell
32	Addiction: Cannabis	$64 Bn (U.S.) in '21 (c)	Pre-clinical	Pre-IND ready for	Phase 1	Drafting
33	Dependence	submission
34
35	CanQuit
36	Addiction: Tobacco Smoking	$47.75 Bn (Global) by '24, 17.3% CAGR (o)	Pre-clinical	Pre-regulatory	Phase 1	Granted
37	Cessation
38	CanQuit O
39	Addiction: Opioid Addiction	$64 Bn (U.S.) in '21 (c)	Pre-clinical	Pre-regulatory	Phase 1	Granted
40	APIRx-1601
41	Skin: Vitiligo	$0.1B (Global) in '21 (b)	Phase 2 complete	Pre-IND drafting	Phase 1	2x granted, 1x
42	pending
43
44	APIRx-1602
45	Skin: Psoriasis	$0.5B (Global) in '21 (b)	Phase 2A complete	Pre-IND drafting	Phase 1	2x granted, 1x
46	pending
47
48	APIRx-1603
49	Skin: Atopic Dermatitis	$1.1B (Global) in '21 (b)	Phase 2A complete	Pre-IND drafting	Phase 1	2x granted, 1x
50	pending
51
52	APIRx-1701
53	Opth: Glaucoma	$10.4B (Global) by '26, 6.3% CAGR (g)	Pre-clinical	Pre-regulatory	in vitro studies	Granted
54	APIRx-1702
55	Opth: Dry Eye Syndrome	$6.6B (Global) by '27, 6.4% CAGR (p)	Pre-clinical	Pre-regulatory	in vitro studies	Granted
56	APIRx-1801
57	Ultrapure THC	$31.5 Bn (Global) by '30; 18.6% CAGR (q)	Developed			Granted
58	APIRx-1802
59	Ultrapure CBD	$31.5 Bn (Global) by '30; 18.6% CAGR (q)	Developed			Granted
60	APIRx-1803
61	Ultrapure CBG	$31.5 Bn (Global) by '30; 18.6% CAGR (q)	Developed			Granted